Semaglutide, a glucagon like peptide-1 (GLP-1) receptor agonist, is offered as monotherapy in both equally subcutaneous as well as oral dosage form (first accepted oral GLP-1 receptor agonist). It has been accepted as being a next line procedure option for better glycaemic control in style two diabetes and presently under https://jacks998epa1.wikicorrespondent.com/user